Galectin‐3 and risk of ischaemic stroke: Reasons for Geographic and Racial Differences in Stroke cohort

Arora, Pankaj; Agarwal, Zubin; Venkatraman, Anand; Callas, Peter W.; Kissela, Brett M.; N, Jenny; Judd, Suzanne E.; Zakai, Neil A.; Cushman, Mary

doi:10.1111/ene.13440

Cited by 14 publications

(12 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies showed that elevated galectin‐3 was associated with incident ischaemic stroke in young individuals , as well as cerebrovascular ischaemic events in patients who underwent carotid endarterectomy . Meanwhile, a case–control study showed that galectin‐3 was significantly higher in patients with poor functional outcomes than in those with good outcomes .…”

Section: Discussionmentioning

confidence: 99%

Association of serum galectin‐3 with risks of death and vascular events in acute ischaemic stroke patients: the role of hyperglycemia

Zeng

Wang

Zhong

et al. 2018

Euro J of Neurology

View full text Add to dashboard Cite

Background and purpose Whether the association between galectin‐3 and stroke outcome is modified by fasting plasma glucose (FPG) is unknown. The aim was to evaluate the prognostic effect of galectin‐3 amongst ischaemic stroke patients stratified by FPG. Methods In all, 3082 ischaemic stroke patients were included in this study and serum galectin‐3 was tested at baseline. The primary outcome was a composite outcome of death and vascular events, and secondary outcomes were death, stroke recurrence and vascular events within 1 year after stroke. Results Increased galectin‐3 was significantly associated with the primary outcome, stroke recurrence and vascular events in the patients with hyperglycemia but not in those with normoglycemia (P for interaction < 0.05 for all). The multivariate‐adjusted hazard ratios (95% confidence intervals) were 1.72 (1.05–2.84), 2.64 (1.14–6.12) and 2.68 (1.33–5.38) for the primary outcome, stroke recurrence and vascular events, respectively. A linear association between galectin‐3 and the primary outcome was observed in hyperglycemic patients (P for linearity = 0.007). Conclusion Increased galectin‐3 was associated with the primary outcome, stroke recurrence and vascular events within 1 year after stroke in the patients with hyperglycemia, suggesting that galectin‐3 may be an important prognostic factor for ischaemic stroke patients with hyperglycemia.

show abstract

Section: Discussionmentioning

confidence: 99%

Association of serum galectin‐3 with risks of death and vascular events in acute ischaemic stroke patients: the role of hyperglycemia

Zeng

Wang

Zhong

et al. 2018

Euro J of Neurology

View full text Add to dashboard Cite

show abstract

“…A prospective longitudinal cohort study enrolled 30 239 patients in the Southeastern United States between 2003 and 2007, and determined baseline plasma galectin-3 levels for 1453 participants selected by a stratified sampling method to include high-risk groups. 130 Within this cohort of 1453 people, by 2011, a total of 526 developed an ischemic stroke. Using a case-cohort study design, serum galectin-3 levels in the upper 2 quartiles were associated with 2.3-fold increased stroke risk (95% CI = 1.6-3.4).…”

Section: Lifestylementioning

confidence: 99%

Galectins in the Pathogenesis of Cerebrovascular Accidents: An Overview

2019

View full text Add to dashboard Cite

Due to limitations of neuroimaging, such as the isodense appearance of blood to neuronal tissue in subacute hemorrhagic stroke, a body of studies have been performed to evaluate candidate biomarkers which may aid in accurate determination of cerebrovascular accident type. Beyond aiding in the delineation of stroke cause, biomarkers could also confer useful prognostic information to help clinicians plan use of resources. One of the candidate biomarkers studied for detection of cerebrovascular accident (CVA) includes a class of proteins called galectins. Galectins bind β-galactoside through a highly conserved carbohydrate recognition domain, endowing an ability to interact with carbohydrate moieties on glycoproteins, some of which are relevant to CVA response. Furthermore, galectins-1, -2, -3, -9, and -12 are expressed in tissues relevant to CVA, and some exhibit characteristics (eg, extracellular secretion) that could render feasible their detection in serum. Galectins-1 and -3 appear to have the largest amounts of preclinical evidence, consistently demonstrating increased activity and expression levels during CVA. However, a lack of standardization of biochemical assays across cohort studies limits further translation of these basic science studies. This review aims to increase awareness of the biochemical roles of galectins in CVA, while also highlighting challenges and remaining questions preventing the translation of basic science observations into a clinically useful test.

show abstract

“…A recent study based on the REGARDS cohort of blacks and whites found that Galectin-3 levels were associated with ischemic stroke incidence in individuals who were younger than 64 years of age [3] . The reason for such an association with age is not clear, but it is possible that levels correlate with a generalized worsening of metabolic syndrome markers, which are more likely to pass the diagnostic threshold later in life.…”

Section: Ischemic Strokementioning

confidence: 99%

“…Although most of the attention in the research literature on the carbohydrate-binding lectin Galectin-3 has focused on cardiovascular pathology [1] , especially in heart failure [2] , there have been some recent studies discussing its role in cerebrovascular disease [3,4] . However, the results of these studies have not been completely consistent with each other [5][6][7][8] , and awareness in the neurosciences community about this biomarker remains limited.…”

Section: Introductionmentioning

confidence: 99%

The Role of Galectin-3 in Stroke and Diseases of the Cerebrovascular System

Venkatraman¹,

Khawaja²,

Kumar³

2018

Med One

View full text Add to dashboard Cite

The carbohydrate binding molecule Galectin-3 has been the focus of recent study in a variety of disease processes, and there is evidence that it plays a role in diseases of the cerebrovascular system. In this review, we summarize the relevant clinical literature on the role of Galectin-3 in ischemic stroke, intracranial hemorrhage and subarachnoid hemorrhage. We also provide a brief overview of the cellular and molecular mechanisms behind the role played by Galectin-3 following ischemic brain injury. Our review is aimed at clinicians who manage these conditions, and neuroscientists who study the role of biomarkers in cerebrovascular disease.

show abstract

Galectin‐3 and risk of ischaemic stroke: Reasons for Geographic and Racial Differences in Stroke cohort

Abstract: Galectin-3 was associated with incident ischaemic stroke in younger but not older individuals. Confirmation of this finding, and elucidation of its implications for stroke pathophysiology and prevention, is needed.

Cited by 14 publications

References 30 publications

Association of serum galectin‐3 with risks of death and vascular events in acute ischaemic stroke patients: the role of hyperglycemia

Association of serum galectin‐3 with risks of death and vascular events in acute ischaemic stroke patients: the role of hyperglycemia

Galectins in the Pathogenesis of Cerebrovascular Accidents: An Overview

The Role of Galectin-3 in Stroke and Diseases of the Cerebrovascular System

Contact Info

Product

Resources

About